You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
|
|---|---|
| Published in |
BMC Cancer, August 2011
|
| DOI | 10.1186/1471-2407-11-349 |
| Pubmed ID | |
| Authors |
Marcia S Brose, Christopher M Nutting, Steven I Sherman, Young Kee Shong, Johannes WA Smit, Gerhard Reike, John Chung, Joachim Kalmus, Christian Kappeler, Martin Schlumberger |
| Abstract |
The incidence of thyroid cancer and the number of patients who die from this disease are increasing globally. Differentiated thyroid cancer (DTC) is the histologic subtype present in most patients and is primarily responsible for the increased overall incidence of thyroid cancer. Sorafenib is a multikinase inhibitor that targets several molecular signals believed to be involved in the pathogenesis of thyroid cancer, including those implicated in DTC. In phase II studies of patients with DTC, sorafenib treatment has yielded a median progression-free survival (PFS) of 58 to 84 weeks and disease control rates of 59% to 100%. The DECISION trial was designed to assess the ability of sorafenib to improve PFS in patients with locally advanced or metastatic, radioactive iodine (RAI)-refractory DTC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| France | 1 | <1% |
| Brazil | 1 | <1% |
| China | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 96 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 14% |
| Student > Ph. D. Student | 12 | 12% |
| Other | 10 | 10% |
| Student > Master | 8 | 8% |
| Professor | 8 | 8% |
| Other | 30 | 29% |
| Unknown | 20 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 52% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 7% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Agricultural and Biological Sciences | 3 | 3% |
| Nursing and Health Professions | 3 | 3% |
| Other | 9 | 9% |
| Unknown | 23 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2015.
All research outputs
#6,992,485
of 22,925,760 outputs
Outputs from BMC Cancer
#1,846
of 8,333 outputs
Outputs of similar age
#39,004
of 121,146 outputs
Outputs of similar age from BMC Cancer
#23
of 106 outputs
Altmetric has tracked 22,925,760 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 8,333 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,146 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.